AbbVie reported mixed fourth-quarter results, with strong growth in immunology and neuroscience drugs countering weakness in its aesthetics portfolio and broader pricing headwinds. While revenue slightly missed estimates, adjusted earnings per share beat expectations.
AbbVie reported record full-year revenue and earnings for 2025, significantly exceeding its initial guidance. The company's growth was driven by its immunology blockbusters Skyrizi and Rinvoq, a rapidly expanding neuroscience portfolio, and strategic acquisitions, successfully offsetting the steep decline of its former top-seller Humira.
In a pivotal virtual briefing, Minerva Neurosciences detailed its confirmatory Phase 3 trial design for roluperidone, a potential first-in-class therapy for the persistent and disabling negative symptoms of schizophrenia, with top-line results expected by late 2027.
Neuroscience analytics firm IXICO appoints industry veteran Tanya Voloshen as its first Chief Commercial Officer, signaling a strategic push to expand its commercial operations and deepen its presence in the critical U.S. market.
Eli Lilly's fourth-quarter revenue surged 42.6%, fueled by overwhelming demand for its weight-loss and diabetes treatments. The pharmaceutical giant's robust performance and bullish outlook underscore its dominant position in the fast-growing GLP-1 market.
Biogen (BIIB) is set to report fourth-quarter earnings before the bell Friday, with Wall Street anticipating a year-over-year revenue decline. The results come amid a mixed landscape for biotechnology peers and broader economic uncertainties.
Despite posting quarterly results that exceeded analyst expectations, shares of Boston Scientific and AbbVie fell sharply as investors scrutinized underperformance in key business units and expressed caution over forward-looking statements.
Barclays and Scotiabank have raised their price targets for Teva Pharmaceutical following its better-than-expected Q4 2025 results and a key pediatric approval for its migraine drug AJOVY, signaling growing confidence in the generic drugmaker's turnaround trajectory.
AbbVie (NYSE: ABBV) reported fourth-quarter 2025 revenue of $16.62 billion, a 10% year-over-year increase that surpassed Wall Street forecasts. Adjusted earnings per share of $2.71 also topped consensus estimates, signaling resilience in its growth strategy.
Spain has unveiled a plan to ban social media access for children under 16, part of a coordinated European push to regulate online platforms and protect minors from digital harms, as similar restrictions gain momentum worldwide.
Alector (ALEC) faces a complex investor landscape following its removal from a key index and a mixed analyst update that raises its price target while maintaining a cautious rating, as the biotech firm grapples with significant projected revenue declines.
As the Australian market braces for an RBA rate decision, a select group of technology and biotech firms are charting distinct paths, balancing innovation investment against shifting economic tides. We examine the prospects for Cogstate, Clinuvel Pharmaceuticals, and PYC Therapeutics.
Truist Securities has raised its price target on Jazz Pharmaceuticals (JAZZ) to $230, citing 'practice-changing' results from the HERIZON-GEA trial for its drug Zepzelca in gastroesophageal adenocarcinoma. The firm maintains a Buy rating, anticipating strong commercial adoption and potential guideline inclusion.
As AbbVie navigates a pivotal year for its key drugs and pipeline, Wall Street analysts are offering mixed signals. While Citi adopts a cautious stance, Berenberg raises its price target, highlighting the contrasting perspectives on the pharmaceutical giant's future.
Pharmaceutical giant Eli Lilly announces a major investment in a new Lehigh Valley manufacturing site, set to create hundreds of jobs and bolster U.S. production capacity for its in-demand injectable therapies, including weight-loss drugs.
All eyes are on AbbVie as it prepares to release its fourth-quarter earnings. With a history of topping revenue forecasts, the market watches to see if its strategic shifts can continue to deliver amid evolving industry pressures.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
Medtronic's expanded partnership with Mindray integrates its monitoring technologies into ASC-focused platforms, a strategic move to embed itself in a high-growth segment while analysts debate its impact on the broader investment thesis.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
